Mustang Bio (NASDAQ: MBIO) has appointed Martina Sersch to serve as chief medical officer. Sersch comes to New York-based Mustang from Amgen (NASDAQ: AMGN), where she was executive director. Mustang is developing cell therapies to treat cancer and gene therapies to treat rare, genetic disorders.
Sponsored · Webinar
Phenotypic Screening & Profiling to Understand a Compound's Disease Impact
Eurofins Discovery
Sponsored · Whitepaper
Explore the different sources of funding, their relative merits, and how you should best utilize that funding at each stage of your research
Brex
Sponsored · Whitepaper
How incorporating more virtual/hybrid trials and decentralized research into clinical development can better integrate healthcare into patients’ real lives and accelerate approval of new medications.
Medpace
